Jin Qiu-Yang, Li Ying-Shuang, Qiao Xing-Hui, Yang Jia-Wei, Guo Xiu-Li
Department of Pharmacology, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, Jinan 250012, PR China.
Department of Pharmacology, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, Jinan 250012, PR China.
Life Sci. 2021 Jul 15;277:119426. doi: 10.1016/j.lfs.2021.119426. Epub 2021 Mar 27.
Over the past few years, tumor immunotherapy has emerged as an innovative tumor treatment and owned incomparable advantages over other tumor therapy. With unique complexity and uncertainty, immunotherapy still need helper to apply in the clinic. Galectins, modulated in tumor microenvironment, can regulate the disorders of innate and adaptive immune system resisting tumor growth. Considering the role of galectins in tumor immunosuppression, combination therapy of targeted anti-galectins and immunotherapy may be a promising tumor treatment. This brief review summarizes the expression and immune functions of different galectins in tumor microenvironment and discusses the potential value of anti-galectins in combination with checkpoint inhibitors in tumor immunotherapy.
在过去几年中，肿瘤免疫疗法已成为一种创新的肿瘤治疗方法，相对于其他肿瘤治疗方法具有无可比拟的优势。由于具有独特的复杂性和不确定性，免疫疗法在临床应用中仍需要辅助手段。半乳糖凝集素在肿瘤微环境中受到调节，可调节抵抗肿瘤生长的先天性和适应性免疫系统的紊乱。考虑到半乳糖凝集素在肿瘤免疫抑制中的作用，靶向抗半乳糖凝集素与免疫疗法的联合治疗可能是一种有前景的肿瘤治疗方法。本简要综述总结了不同半乳糖凝集素在肿瘤微环境中的表达及免疫功能，并探讨了抗半乳糖凝集素与检查点抑制剂联合用于肿瘤免疫治疗的潜在价值。
